ALMS
Alumis Inc.11.40
+0.09+0.8%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.19BP/E (TTM)
-Basic EPS (TTM)
-2.15Dividend Yield
0%Recent Filings
10-K
FY2025 results
Alumis, a clinical-stage biotech, reported FY2025 net loss of $243.3M on $24.1M collaboration revenue from Kaken deal, up from $294.2M loss in FY2024 with no revenue. R&D expenses rose 45% to $386.0M, driven by Phase 3 ONWARD trials for envu in PsO (positive topline Q1 2026) and Phase 2 SLE topline expected Q3 2026; Q4 momentum evident in accelerated enrollment and manufacturing scale-up. ACELYRIN merger in May added lonigutamab (TED) IPR&D asset ($51.0M) and $188M bargain purchase gain, but drove $56.7M G&A surge from integration/severance. Cash of $308.5M plus $324M Jan 2026 offering funds ops 12+ months. Clinical trial delays from enrollment or AEs could stall NDA filing.
8-K
2025 loss narrows; Ph3 success
8-K
Alumis prices $345M offering
Alumis priced a public offering of 17.65M common shares at $17.00 each on January 7, 2026, expecting $345.1M gross proceeds before expenses; the underwriters exercised their full option for 2.65M more shares. Closing set for January 9. Year-end cash stood at ~$308.6M. Bolsters runway amid clinical pushes.
8-K
Envudeucitinib Phase 3 psoriasis success
Alumis announced positive Phase 3 ONWARD1 and ONWARD2 topline results for envudeucitinib in moderate-to-severe plaque psoriasis on January 6, 2026. Both trials met all primary and secondary endpoints with high significance, averaging 74% PASI 75 and 59% sPGA 0/1 at Week 16, deepening to ~65% PASI 90 and >40% PASI 100 at Week 24. Safety matched Phase 2. NDA submission is planned for H2 2026. Regulatory approval is uncertain.
8-K
Alumis breaches Climb Bio
Alumis issued a notice of material breach to Climb Bio on January 2, 2026, over its refusal to pay a $3,000,000 development milestone due January 1 under the 2024 APA for budoprutug. Climb Bio's Delaware lawsuit claims the drug isn't a 'Product,' clashing with APA terms and its own SEC filings. Alumis will fight for payment, interest, and fees. Litigation outcome remains uncertain.
ACRS
Aclaris Therapeutics, Inc.
3.21+0.04
ALKS
Alkermes plc
28.06-0.11
ALMU
Aeluma, Inc.
16.36-0.22
ALT
Altimmune, Inc.
5.03-0.25
ALVO
Alvotech
5.04-0.36
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ARQT
Arcutis Biotherapeutics, Inc.
28.53-0.42
AUPH
Aurinia Pharmaceuticals Inc
15.85+0.16
IMA
ImageneBio, Inc.
6.25+0.08
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16